Xtrana Wins $400K NIH Grant | GenomeWeb

NEW YORK, Aug. 29 – Xtrana has received a $400,000 Phase I NIH grant to develop nanofluidic nucleic acid preparation components, the company announced Wednesday.

The work will be done in collaboration with researchers at the University of New Mexico and Sandia National Laboratory.

The research builds on Broomfield, Colo.-based Xtrana’s Xtra Bind non-silica-based nucleic acid extraction technology. The application for the nanofluidic technology is to let users run assay panels for infectious diseases and other agents at the site of sample collection, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.